Skip to main content


We're creating a new version of this page. See preview

  • Poster presentation
  • Open Access

Evidences for the need of new Diagnostic Criteria for PFAPA syndrome

  • 1,
  • 2,
  • 3,
  • 2,
  • 1,
  • 4,
  • 5,
  • 6,
  • 7,
  • 1,
  • 1,
  • 8,
  • 2,
  • 1 and
  • 1
Pediatric Rheumatology20086 (Suppl 1) :P181

  • Published:


  • Genetic Test
  • Familial Mediterranean Fever
  • Skin Rash
  • Current Criterion
  • Periodic Fever


The clinical manifestations of PFAPA syndrome largely overlap with those of monogenic Autoinflammatory diseases: Familial Mediterranean Fever (FMF), tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) and Mevalonate kinase deficiency (MKD). Aim of this study is to evaluate the specificity of the available diagnostic criteria for PFAPA.

Patients and methods

307 consecutive patients with a clinical history of periodic fever were screened for mutations of MVK, TNFRSF1A and MEFV genes and detailed clinical information was collected. PFAPA diagnostic criteria were applied in all these patients. The clinical parameters associated with an high risk to be affected by an Autoinflammatory disease were identified on the basis of a univariate and multivariate analysis in both genetically positive and negative patients complying PFAPA criteria.


133 out of 307 patients satisfying PFAPA criteria. 33 carried relevant mutations on the screened genes (27 MKD, 3 TRAPS, 3 FMF), 28 were heterozygous for MEFV mutations, 7 carried R92Q mutation of TNFRSF1A gene, showing the low specificity of current criteria. Rash (OR = 2.975, p = 0.009), abdominal pain (OR = 3.261, p = 0.005) and vomiting (OR = 2.445, p = 0.3) were the variables most correlated to the positivity at the genetic test.


Current PFAPA criteria display a low specificity. According to this study, the presence of gastrointestinal manifestations and skin rash in patients fulfilling the current PFAFA criteria should orientate towards the exclusion of monogenic periodic fevers by molecular analysis. Consistent modifications of ongoing clinical criteria are proposed.

Authors’ Affiliations

UO Pediatria II, G. Gaslini Institute and Department of Pediatrics, University of Genoa, Genova, Italy
Dipartimento di Pediatria, Unità di Immunologia e Reumatologia Pediatrica, Spedali Civili e University of Brescia, Brescia, Italy
Unità di Biostatistica, DISSAL, University of Genoa, Genova, Italy
Dipartimento A.I. di Pediatria, University of Padua, Padova, Italy
Ospedale Pediatrico Bambino Gesu', Roma, Roma, Italy
Unità di Pediatria, Policlinico "G. Martino", Messina, Italy
IRCCS Burlo Garofalo, Dipartimento di Pediatria, University of Trieste, Trieste, Italy
Department of General Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands


© Caorsi et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.